ASK REDCHAT ANYTHING ABOUT LEXICON PHARMACEUTICALS, INC.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)
Listen to this Section
$2.23
+0.0050
(
+0.23% )
0.8K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| INPEFA™ (SOTAGLIFLOZIN)DetailsHeart disease, Heart failure |
Approved |
| XERMELO® (telotristat ethyl)DetailsCarcinoid syndrome diarrhea |
Approved |
| ZYNQUISTA™ (sotagliflozin)DetailsHypertrophic cardiomyopathies |
Phase 3 |
| LX9211DetailsNeuropathy, Diabetic peripheral neuropathy |
Phase 2b |
| ZYNQUISTA™ (sotagliflozin)DetailsType 1 diabetes, Diabetes |
Failed |
Market Data
|
| Open |
$2.23 |
| Previous Close |
$2.22 |
| Volume |
0.8K |
| Market Cap |
$986.12M |
| Day Range |
$2.24 - $2.26 |
| 52 Week Range |
$1.00 - $2.68 |
| Shares Outstanding |
444.20M |
| Change % |
+0.23% |
| Net Change |
▲ 0.0050 |
| Insider Ownership |
-0.06% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Year | 2000 |
| Country | United States |
Insider Ownership Transactions
Total Amount Purchased:
-63,152,917.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-09-14 |
Buy |
10000.00 |
WADE JEFFREY L |
| 2023-08-07 |
Buy |
6000.00 |
McDermott Wendy |